Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 5, 2014, Pages 480-488

  Hermos, John A ^a,b   Quach, Lien ^a   Gagnon, David R ^a,c   Weber, H Christian ^a,b   Altincatal, Arman ^a   Cho, Kelly ^a,d   Lawler, Elizabeth V ^a,d   Grotzinger, Kelly M ^e  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Hepatitis C; Interferon; Pharmacoepidemiology; Thrombocytopenia; Veterans

Indexed keywords

HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VETERAN; DRUG COMBINATION; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; UNITED STATES; VETERANS;

EID: 84898051810     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3585     Document Type: Article

References (28)

1. Wang C-S, Yao W-J, Wang S-T, Chang T-T, Chou P. Strong association of Hepatitis C Virus (HCV) infection and thrombocytopenia: implications for a survey of a community with hyperendemic HC infection. Clin Infect Ds 2004; 39: 790-6.
2. Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007; 26(Suppl 1): 5-11.
3. Afdhal N, McHutchison J, Brown R, et al. Review: thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48: 1000-10.
4. Pluta A, Gutkowski K, Sawka D. Thrombocytopenia in hepatitic C infection and chronic liver disease. Exp Clin Hepatol 2009; 5: 15-19.
5. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-38.
6. Louis KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepatitis 2011; 18: 1-7.
7. Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monothreapy for chronic hepatitis C-an updated Cochrane review. Aliment Pharmacol Ther 2010; 32: 840-850.
8. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
9. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Amer J Gastroenterol 2012; 107: 669-689.
10. El-Serag HB. Epidemiology of hepatitis C and hepatocellular carcinoma. Gastroenterol 2012; 142: 1224-1273.
11. Estaban R, Buti M. Triple therapy with boceprevir or telaprevir for treatment of naive HCV patients. Best Pract Res Clin Gastroenterol 2012; 26: 445-453.
12. Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir and telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatol 2012; 56: 850-860.
13. Kiernan J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. CID 2013; 56; 228-235.
14. Nachnani JS, Rao GA, Bulchandani D, Pandya PK, Alba LM. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribaviron. Ann Hematol 2010; 89: 121-125.
15. Roomer R, Hansen B, Janssen HLA, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 2010; 53: 455-459.
16. Lin K-H, Hsu P-I, Kin C-K, et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and pretreatment low platelet counts. BMC Gastroenterol 2012; 12: 7.
17. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
18. Fried M. Side effects of therapy of hepatitis C and their management. Hepatol 2002; 36(Suppl. 1): S237-S244.
19. Giannini EG. Thrombocytopenia in patients with chronic liver disease: what's in a name? Dig Dis Sci 2013; 58: 299-301.
20. Hermos JA, Altincatal A, Weber HC, et al. Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease. Dig Dis Sci 2013; 58: 562-573.
21. Brown RS Jr., Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007; 26(Suppl 1): 41-48.
22. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical resource utilization in healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. J Med Econ 2011; 14: 194-206.
23. Dominitz JA, Boyke EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States Veterans Medical Centers. Hepatology 2005: 41: 88-96.
24. Austin GE, Jensen B, Leete J, et al. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. Am J Med Sci 2000; 319: 353-359.
25. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001; 34: 1200-1205.
26. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
27. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterol 2012; 142: 1340-1350.
28. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 26: 1055-1065.